Discovery and preclinical evaluation of a novel highly selective and potent CDK12 inhibitor

被引：0

作者：

Yamakawa, Hiroko ^{[1
]}

Mizutani, Akio ^{[1
]}

Arikawa, Yasuyoshi ^{[1
]}

Ebara, Shunsuke ^{[1
]}

Satoh, Yoshihiko ^{[1
]}

Morishita, Daisuke ^{[1
]}

机构：

[1] Chordia Therapeut Inc, Fujisawa, Kanagawa, Japan

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5485

引用

页数：1

共 50 条

[21] Discovery of a novel and highly selective CDK9 kinase inhibitor (JS']JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models
Wang, Li
Hu, Chen
Wang, Aoli
Chen, Cheng
Wu, Jiaxin
Jiang, Zongru
Zou, Fengming
Yu, Kailin
Wu, Hong
Liu, Juan
Wang, Wenliang
Wang, Zuowei
Wang, Beilei
Qi, Ziping
Liu, Qingwang
Wang, Wenchao
Li, Lili
Ge, Jian
Liu, Jing
Liu, Qingsong
INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1272 - 1281
[22] OKI-1546 is a selective, orally bioavailable inhibitor of CDK12 that causes tumor regression in multiple preclinical cancer models
Strait, Alexander A.
Mareska, David A.
Mahadevan, Jyothi
Schulte, Christie A.
Izrayelit, Yevgeniy
Boys, Mark L.
Woessner, Richard
CANCER RESEARCH, 2023, 83 (07)
[23] Pharmacological characterization of a preclinical candidate covalently inhibiting CDK12
Poddutoori, Ramulu
Rajagopalan, Sujatha
Mukherjee, Subhendu
Marappan, Sivapriya
Samiulla, D. S.
Sivakumar, Sasirekha
Nayak, Shilpa S.
Ravindra, M., V
Devaraja, T. S.
Kondela, Srinivas
Tgore, Suraj
Dhudashiya, Amit A.
Charamanna, K. B.
Aravind, A. B.
Amith, A.
Pavithra, S.
Pathange, Hema Sankar
Antony, Thomas
Jaleel, Mahaboobi
Giri, Sanjeev
Daginakatte, Girish
Nellore, Kavitha
Chelur, Shekar
Ramachandra, Murali
Samajdar, Susanta
CANCER RESEARCH, 2019, 79 (13)
[24] An oral and selective CDK12 inhibitor demonstrates robust anti-tumor activity
Hu, Shanhu
Moebius, David
Dworakowski, Wojciech
Cooper, Elliott
LaPlaca, Derek
Alnemy, Sydney
Perera, Phone
Marineau, Jason
Chuaqui, Claudio
Carulli, John P.
Olson, Eric
CANCER RESEARCH, 2022, 82 (12)
[25] CDK12: A Potent Target and Biomarker for Human Cancer Therapy
Liang, Shujing
Hu, Lifang
Wu, Zixiang
Chen, Zhihao
Liu, Shuyu
Xu, Xia
Qian, Airong
CELLS, 2020, 9 (06) : 1 - 15
[26] CDK12 is a novel therapeutic target in glioblastoma
Mun, Jeong-Yeon
Shu, Chang
Gao, Qiuqiang
Westhoff, Mike-Andrew
Karpel-Massler, Georg
Siegelin, Markus D.
CANCER RESEARCH, 2024, 84 (06)
[27] Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor.
Peng, Sheng-Bin
Si, Chong
Zhang, Youyan
Van Horn, Robert D.
Lin, Xi
Gong, Xueqian
Huber, Lysiane
Donoho, Gregory
Curtis, Carmen
Strelow, John M.
Bocchinfuso, Wayne P.
Guo, Deqi
Boulet, Serge L.
Barda, David
Manglicmot, Danalyn
Saflor, Melbert-Brian D.
Wang, Jing
Xiao, Junpeng
Chalmers, Michael J.
Burns, Lee
Linder, Ryan J.
Ackermann, Bradley L.
Cornwell, Paul D.
Zhou, Lian
McCann, Denis
Henry, James
CANCER RESEARCH, 2021, 81 (13)
[28] MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer
Hanghang Zhang
Chen Huang
John Gordon
Sijia Yu
George Morton
Wayne Childers
Magid Abou-Gharbia
Yi Zhang
Jaroslav Jelinek
Jean-Pierre J. Issa
Clinical Epigenetics, 16
[29] MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer
Zhang, Hanghang
Huang, Chen
Gordon, John
Yu, Sijia
Morton, George
Childers, Wayne
Abou-Gharbia, Magid
Zhang, Yi
Jelinek, Jaroslav
Issa, Jean-Pierre J.
CLINICAL EPIGENETICS, 2024, 16 (01)
[30] Discovery of PF-07220060, a potent and selective CDK4 inhibitor
Anders, Lars
Gallego, Gary
CANCER RESEARCH, 2024, 84 (07)

← 1 2 3 4 5 →